| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/04/2009 | US20090142783 Human p51 Genes and Gene Products Thereof |
| 06/04/2009 | US20090142782 Using actinobacillus specific immunogolbulins to diagnose gum disease |
| 06/04/2009 | US20090142778 Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
| 06/04/2009 | US20090142427 Composition and its Therapeutic Use |
| 06/04/2009 | US20090142409 Extracellular Matrix Compositions for Tissue Regeneration |
| 06/04/2009 | US20090142408 Telomerase delivery by biodegradable Nanoparticle |
| 06/04/2009 | US20090142407 Solid peptide preparations for inhalation and their preparation |
| 06/04/2009 | US20090142405 Bioactive agent, a low molecular weight chitosan, and a negatively charged third component; the chitosan dominates on the nanoparticle surface; enhanced permeability for paracellular drug delivery; chewable composition |
| 06/04/2009 | US20090142403 Organ regeneration device |
| 06/04/2009 | US20090142399 Dispersant agent for sustained-release preparations |
| 06/04/2009 | US20090142397 Reduction of dermal scarring |
| 06/04/2009 | US20090142396 Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects |
| 06/04/2009 | US20090142386 Control of drug release by transient modification of local microenvironments |
| 06/04/2009 | US20090142385 Compositions for treating bone defects |
| 06/04/2009 | US20090142376 Chlamydia polypeptides and corresponding dna fragments and uses thereof |
| 06/04/2009 | US20090142364 Method for finding novel peptide immunostimulatory adjuvants, compositions and methods of use |
| 06/04/2009 | US20090142360 Use of ferritin to treat iron deficiency disorders |
| 06/04/2009 | US20090142359 Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells; treating cancer by Her2 overexpression using the antibodies |
| 06/04/2009 | US20090142353 Human Tumor Necrosis Factor Receptor TR17 |
| 06/04/2009 | US20090142351 Human and rat PGC-3, PPAR-gamma coactivations and splice variants thereof |
| 06/04/2009 | US20090142342 B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
| 06/04/2009 | US20090142341 Mutated pseudomonas exotoxins with reduced antigenicity |
| 06/04/2009 | US20090142336 Metabolic regulators and uses thereof |
| 06/04/2009 | US20090142335 Methods of diagnosis and treatment of metabolic disorders |
| 06/04/2009 | US20090142334 DETECTION AND MODULATION OF IAPs AND NAIP FOR THE DIAGNOSIS AND TREATMENT OF PROLIFERATIVE DISEASE |
| 06/04/2009 | US20090142333 Activin-actriia antagonists and uses for promoting bone growth in cancer patients |
| 06/04/2009 | US20090142330 Use of inactive-plasmin to treat chronic inflammatory disease and tumors |
| 06/04/2009 | US20090142329 Interleukin-1 Beta Converting Enzyme Like Apoptosis Protease-3 and 4 |
| 06/04/2009 | US20090142328 Uses of antileukoprotease in carcinoma |
| 06/04/2009 | US20090142327 Novel Class of Therapeutic Protein Based Molecules |
| 06/04/2009 | US20090142326 Glycosidase Enzymes |
| 06/04/2009 | US20090142325 Compositions and methods for treating tumour spreading |
| 06/04/2009 | US20090142323 Methods for treating a disorder by regulating gprc6a |
| 06/04/2009 | US20090142322 Coenzyme Q10 Production in a Recombinant Oleaginous Yeast |
| 06/04/2009 | US20090142312 Methods for Promoting Wound Healing and Muscle Regeneration with the Cell Signaling Protein Nell1 |
| 06/04/2009 | US20090142311 Engineered intervertebral disc tissue |
| 06/04/2009 | US20090142310 Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides |
| 06/04/2009 | US20090142309 Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| 06/04/2009 | US20090142301 Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases |
| 06/04/2009 | US20090142300 Compositions and methods related to toll-like receptor-3 |
| 06/04/2009 | US20090142299 Macrocyclic tetrazolyl hepatitis c serine protease inhibitors |
| 06/04/2009 | US20090142298 Apolactoferrin Compositions and Methods for Their Use in the Treatment of Viral Hepatitis C |
| 06/04/2009 | US20090142297 5-substituted isoindoline compounds |
| 06/04/2009 | US20090142296 Method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue |
| 06/04/2009 | US20090142295 Anti-Connexin Compounds and Uses Thereof |
| 06/04/2009 | US20090142294 Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes |
| 06/04/2009 | US20090142283 Peptide-based antidandruff reagents |
| 06/04/2009 | US20090142281 Composition Comprising A Coupled Enzyme System |
| 06/04/2009 | US20090142280 Protective skin care peptides |
| 06/04/2009 | US20090142259 Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors |
| 06/04/2009 | DE19549852B4 Cyclosporin enthaltende Präparate Cyclosporin-containing preparations |
| 06/04/2009 | DE102007059924A1 Allel- und Isotyp-spezifische Intervention an mit Autoimmunerkrankungen assoziierten MHC-Klasse-II-Molekülen durch Peptide Allelic and isotype-specific intervention in associated with autoimmune diseases MHC class II molecules by peptides |
| 06/04/2009 | CA2802984A1 Use of eph-b4 and ephrin-a1 for predicting negative physiological response to the treatment with erythropoietin |
| 06/04/2009 | CA2707117A1 Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders |
| 06/04/2009 | CA2707096A1 Composition for treatment and prevention of hair loss and premature graying of hair |
| 06/04/2009 | CA2706800A1 Novel use |
| 06/04/2009 | CA2706742A1 Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent |
| 06/04/2009 | CA2706627A1 A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| 06/04/2009 | CA2706479A1 14-3-3 antagonists for the prevention and treatment of arthritis |
| 06/04/2009 | CA2705977A1 Use of somatostatin analogs in meningioma |
| 06/04/2009 | CA2704704A1 Composition comprising calcium ions and at least one proteolytic enzyme for use in the in vitro and in vivo regeneration of cutaneous and connective tissues |
| 06/03/2009 | EP2065468A1 Modifications of hiv env enhance immunogenicity for genetic immunization |
| 06/03/2009 | EP2065396A1 Interleukin-19 |
| 06/03/2009 | EP2065053A1 Cell death inhibitor |
| 06/03/2009 | EP2065051A2 Composition for maintaining gastrointestinal homeostasis comprising albumin and tannic acid |
| 06/03/2009 | EP2065050A1 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| 06/03/2009 | EP2065044A1 Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators |
| 06/03/2009 | EP2065034A2 Enteric-coated glucosinolates and beta-thioglucosidases |
| 06/03/2009 | EP2064951A1 Use of a substituted imidazole, derivatives or salts thereof for the preparation of a medicament for the treatment of a cell proliferative disorder |
| 06/03/2009 | EP2064238A1 Crystal structure of the thsr receptor |
| 06/03/2009 | EP2064237A2 Il-17c antagonists and methods of using the same |
| 06/03/2009 | EP2064235A1 The death receptor cd95 controls neurogenesis of adult neural stem cells in vivo and in vitro |
| 06/03/2009 | EP2064228A2 Synthetic peptide amides |
| 06/03/2009 | EP2063910A2 Method of treating endothelial dysfunction |
| 06/03/2009 | EP2063909A1 Formulations for therapeutic administration of thyroid stimulating hormone (tsh) |
| 06/03/2009 | EP2063908A2 Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection |
| 06/03/2009 | EP2063907A2 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
| 06/03/2009 | EP2063906A1 Methods and compositions for promoting organ development |
| 06/03/2009 | EP2063905A2 Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
| 06/03/2009 | EP2063904A1 Methods involving lef-1 regulation and use of lef-1 or compounds altering lef-1 signalling for treating or preventing diseases |
| 06/03/2009 | EP2063903A1 Pulmonary surfactant formulations and methods for promoting mucus clearance |
| 06/03/2009 | EP2063880A2 Composition for the treatment of amyotrophic lateral sclerosis |
| 06/03/2009 | EP2063875A2 Combination pharmaceutical compositions |
| 06/03/2009 | EP2063808A2 Absorbent fabric implant |
| 06/03/2009 | EP1874341B1 Erythrocytes containing arginine deiminase |
| 06/03/2009 | EP1763363B1 Diaminooxidase-containing pharmaceutical compositions |
| 06/03/2009 | EP1682546B1 Peptidomimetic compounds, stereoselective process for their preparation, their use as biologically active synthetic intermediates |
| 06/03/2009 | EP1660135B1 Method of treating hepatocellular carcinoma |
| 06/03/2009 | EP1620456A4 Hla-a2 tumor associated antigen peptides and compositions |
| 06/03/2009 | EP1562629B1 Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2 |
| 06/03/2009 | EP1480618B1 Sustained release drug formulations containing a carrier peptide |
| 06/03/2009 | EP1435906B1 Method for producing biologically active products |
| 06/03/2009 | EP1399472B1 Soluble heterodimeric cytokine receptor |
| 06/03/2009 | EP1295943B1 Polypeptides having activity of stimulating neutrophils |
| 06/03/2009 | EP1218544B1 TAR RNA binding peptides |
| 06/03/2009 | EP1187636B1 Injectable hyaluronate-sulfated polysaccharide conjugates |
| 06/03/2009 | EP1131426B1 Mage-10 or mage-8 derived hla-a2.1-binding oligopeptides |
| 06/03/2009 | EP1111054B1 A new gene of human lysoenzyme, the encoding polypeptide and methods for preparing them |
| 06/03/2009 | EP1035836B1 Composition comprising an enzym, a stabilizer for the enzym and a process for ameliorating the stability of the enzyme, to prevent its degradation, to protect it and/or to immobilise it |
| 06/03/2009 | EP1012283B1 Mage-3 peptides presented by hla class ii molecules |